

Clinical and Immunologic effect of IORT in Pancreatic Cancer Surgery

JOON SEONG PARK, M.D., Ph.D..


Department of Surgery

Seoul National University College of Medicine, Korea

Disclosure Statement of Financial Interest

“No COI”


Expected Incidence of PDAC in Korea



Annual number of incidence of PDAC is rapidly increasing

Park HM et al. J Korean Med Sci, 2022


Pancreatic cancer is still poor prognosis



Negative margins are the goal
with Radical Resection for PDAC

Definition of resection margin

- **Tumor free margin > 1mm**
- Ink marking of the different Resection margin
- Axial dissection technique
- Remaining difficulty in differentiation of pancreatic, ampullar and distal bile duct cancers




Verbeke CS. Histopathology 2008;52:787-796


Pancreatic Cancer Surgery

The New R-status Counts

Oliver Strobel, MD,* Thomas Hank, MD,* Ulf Hinz, MSc,* Frank Bergmann, MD,† Lutz Schneider, MD,*
 Christoph Springfeld, MD, PhD,‡ Dirk Jäger, MD,‡ Peter Schirmacher, MD,† Thilo Hackert, MD,*
 and Markus W. Büchler, MD*




Retroperitoneal Resection Margin ?



Detailed Analysis of Margin Positivity and the Site of Local Recurrence After Pancreaticoduodenectomy



Caitlin A. McIntyre, MD¹, Constantinos P. Zambirinis, MD, MRes¹, Alessandra Pulvirenti, MD¹, Joanne F. Chou, MPH², Mithat Gonen, PhD², Vinod P. Balachandran, MD¹, T. Peter Kingham, MD¹, Michael I. D'Angelica, MD¹, Murray F. Brennan, MD¹, Jeffrey A. Drebin, MD, PhD¹, William R. Jarnagin, MD¹, and Peter J. Allen, MD^{1,3}

- Local failure rate : 44.8%
- Retroperitoneal margin positive



	Univariate analysis		Multivariate analysis	
	HR (95% CI)	p value	HR (95% CI)	p value
Positive posterior margin	1.50 (1.17–1.91)	0.001	1.41 (1.09–1.81)	0.009
Positive pancreatic margin	1.06 (0.78–1.43)	0.707		
Positive bile duct margin	0.85 (0.42–1.72)	0.654		
Positive anterior peritoneal margin	1.02 (0.65–1.59)	0.913		
Positive lymph nodes	1.36 (1.06–1.75)	0.017	1.13 (0.85–1.49)	0.400
Tumor size	1.09 (0.99–1.19)	0.068	1.06 (0.97–1.17)	0.210
Poor tumor differentiation	0.96 (0.75–1.24)	0.766		
Lymphovascular invasion	1.26 (1.00–1.60)	0.054	1.08 (0.84–1.39)	0.550
Perineural invasion	1.61 (0.97–2.65)	0.063	1.35 (0.81–2.24)	0.250

Margin status & Prognosis after pancreatectomy(SNUH)



1 mm margin (+) 43%

0 mm margin (+) 17%

Unpublished

IORT [Intraoperative radiation therapy]

- **High doses of radiation therapy while excluding part or all of the nearby dose-limiting sensitive structures**
- **The effective radiation dose is increased and local tumor control potentially improved**
- **In pancreatic cancer, IORT has been offered for unresectable tumors to provide local tumor control and palliation of pain, and for resectable tumors in an effort to improve local control and survival after PD**

Advantages of IORT

1. **Reduce the chance of residual tumor** at the site of surgery, thus maximizing local control and reducing of local recurrence
2. **Maximizes the radiobiological effect** of a single high dose
3. **Faster treatment time**
4. **Minimal exposure of surrounding tissues** to radiation, thus reducing normal tissue toxicity

First IORT in Korea (1986)

Electron IORT for Gastric cancer

- 20-Gy single fraction equivalent to 40-60 Gy at 2 Gy/fx
- **Advantage**
 - ✓ Normal tissue sparing, early application of RT, visual target, increased effective dose to tumor bed
- **Disadvantage**
 - ✓ No pre-treatment planning, uncertainty in dose distribution, **patient transport**, development of IMRT



First case of IORT : Sep-26-2017

Intraoperative Radiation Therapy for Resectable **Pancreatic Cancer**

• Resectable **Pancreatic**
Adenocarcinoma

• Radiation: **Intraoperative radiation therapy**
(IORT)

• Gangnam Severance Hospital
Seoul, Korea, Republic of

ClinicalTrials.gov Identifier: NCT03273374

Arm 1

Experimental: **IORT** group

Intraoperative radiation therapy of 10 Gy delivered during surgery followed by adjuvant gemcitabine chemotherapy

Recruitment Status 1 : Recruiting

First Posted 1 : September 6, 2017

Last Update Posted 1 : September 11, 2017

See [Contacts and Locations](#)

STUDY PROTOCOL

Open Access

A phase II study of intraoperative radiotherapy using a low-energy x-ray source for resectable pancreatic cancer: a study protocol



Jun Won Kim¹, Yeona Cho¹, Hyung Sun Kim², Won Hoon Choi¹, Joon Seong Park^{2*} and Ik Jae Lee^{1*}

Curative resection

Determination of IORT Target volume

Selection of applicator
(3.0, 3.5, or 4.0 cm)

Placement of applicator

Irradiation with a single dose of
10 Gy into the tumor bed

Removal of applicator



30-40mins

Intraoperative Radiotherapy for Resectable Pancreatic Cancer Using a Low-Energy X-Ray Source: Postoperative Complications and Early Outcomes

Yeona Cho¹, Jun Won Kim¹, Hyung Sun Kim², Jon Seong Park², and Ik Jae Lee¹

Departments of ¹Radiation Oncology and ²Surgery, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.




Fig. 2. Patients selection for this analysis. IORT, intraoperative radiotherapy.

Table 3. Postoperative Complications (n=41)

Checklist	Grade	n (%)
Delayed Gastric emptying*	A	1 (2.4)
	B	4 (9.8)
Postoperative pancreatic fistula [†]	A	1 (2.4)
	B	1 (2.4)
Chyle leakage	2	2 (4.9)
Duodenal ulcer perforation	3b	1 (2.4)


Other acute postoperative complications were evaluated using Clavien-Dindo classification.

*Delayed gastric emptying was graded according to the International Study Group of Pancreatic Surgery consensus definition; [†]We use the consensus of International Study Group on Pancreatic Fistula (ISGPF) for the definition and grading of postoperative pancreatic fistula.

IORT for Resectable PDAC : Final Results

Table 2 Local recurrence rate and survival rates

	1 year	2 years	3 years
Local recurrence rate (%)	28.2	54.9	70.8
Disease-free survival (%)	48.1	19.5	13.5
Overall survival (%)	92.2	63.6	53.4



Average Local Recurrence Rate \approx 40% at 1yr

The Physiological Effects of IORT

- **Abscopal effect :**


Effects of ionizing radiation at a distance from the irradiated volume but within the same organism

- **Bystander effect :**

Effects of ionizing radiation at normal tissue induced inflammation and cytokine signals

Intraoperative radiation therapy induces immune response activity after pancreatic surgery

Yun Sun Lee^{1,2}, Hyung Sun Kim¹, Yeona Cho³, Ik Jae Lee³, Hyo Jung Kim¹, Da Eun Lee^{1,2}, Hyeon Woong Kang^{1,2} and Joon Seong Park^{1*}




Intraoperative radiation therapy induces immune response activity after pancreatic surgery




Yun Sun Lee^{1,2}, Hyung Sun Kim¹, Yeona Cho³, Ik Jae Lee³, Hyo Jung Kim¹, Da Eun Lee^{1,2}, Hyeon Woong Kang^{1,2} and Joon Seong Park^{1*}

A




B



Intraoperative radiation therapy induces immune response activity after pancreatic surgery


Yun Sun Lee^{1,2}, Hyung Sun Kim¹, Yeona Cho³, Ik Jae Lee³, Hyo Jung Kim¹, Da Eun Lee^{1,2}, Hyeon Woong Kang^{1,2} and Joon Seong Park^{1*}



Intraoperative radiation therapy induces immune response activity after pancreatic surgery




Yun Sun Lee^{1,2}, Hyung Sun Kim¹, Yeona Cho³, Ik Jae Lee³, Hyo Jung Kim¹, Da Eun Lee^{1,2}, Hyun Wook Kang^{1,2} and Jeon Seung Park^{1*}



Intraoperative radiation therapy induces immune response activity after pancreatic surgery

Yun Sun Lee^{1,2}, Hyung Sun Kim¹, Yeona Cho³, Ik Jae Lee³, Hyo Jung Kim¹, Da Eun Lee^{1,2}, Hyeon Woong Kang^{1,2} and Joon Seong Park^{1*}



Conclusions

IORT is safe and some immunologic advantages in PDAC



National Funding

1. National Research Foundation of Korea (NRF) grant funded by the Korean Government, Ministry of Science, and ICT (MSIT) (NRF 2022R1A2C1004141)
2. National R&D Program for Cancer Control through the National Cancer Center(NCC) funded by the Ministry of Health & Welfare, Republic of Korea
3. National Research Foundation of Korea (NRF) grant funded by the Korean Government, Ministry of Science, and ICT (MSIT) (NRF 2022H121C0480)
4. This research was supported by a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (HI23C1591)